Disgruntled Ramius offers $4.00 per share for rest of Cypress Bioscience

20 Jul 2010

• By Peter Mansell

A disgruntled major shareholder has launched a $4.00 per share takeover bid for Cypress Bioscience, the US company best known for its fibromyalgia treatment Savella (milnacipran HCl).

Disgruntled Ramius offers $4.00 per share for rest of Cypress Bioscience

More from Musculoskeletal

More from Therapeutic Category